The aim of this study was to analyze the value of urine αand π-GST in monitoring and predicting kidney graft function following transplantation. In addition, urine samples from corresponding organ donors was analyzed and compared with graft function after organ donation from brain-dead and living donors. Urine samples from brain-dead (n = 30) and living related (n = 50) donors and their corresponding recipients were analyzed before and after kidney transplantation. Urine αand π-GST values were measured. Kidney recipients were grouped into patients with acute graft rejection (AGR), calcineurin inhibitor toxicity (CNI), and delayed graft function (DGF), and compared to those with unimpaired graft function. Urinary π-GST revealed significant differences in deceased kidney donor recipients with episodes of AGR or DGF at day one after transplantation (p = 0.0023 and p = 0.036, respectively). High π-GST values at postoperative day 1 (cutoff: >21.4 ng/mg urine creatinine (uCrea) or >18.3 ng/mg uCrea for AGR or DGF, respectively) distinguished between rejection and no rejection (sensitivity, 100%; specificity, 66.6%) as well as between DGF and normal-functioning grafts (sensitivity, 100%; specificity, 62.6%). In living donor recipients, urine levels of αand π-GST were about 10 times lower than in deceased donor recipients. In deceased donors with impaired graft function in corresponding recipients, urinary αand π-GST were elevated. α-GST values >33.97 ng/mg uCrea were indicative of AGR with a sensitivity and specificity of 77.7% and 100%, respectively. In deceased donor kidney transplantation, evaluation of urinary αand π-GST seems to predict different events that deteriorate graft function. To elucidate the potential advantages of such biomarkers, further analysis is warranted.
Experimental Section

Samples and Data Collection
This study was approved by the Ethics Committee of Berlin's Charité University Hospital (EA2/137/10). We prospectively analyzed blood and urine samples as well as demographic data from 160 patients: 30 brain-dead donors and their 30 corresponding recipients; and 50 living kidney donors as well as their 50 corresponding living donor kidney recipients. All surgeries were carried out at the Department of General, Visceral and Transplantation surgery of Charité University Hospital, Berlin. Machine perfusion was not performed for any kidney allograft in this study. Except for brain-dead donors, all patients were followed during the first week after surgery. Blood and urine samples were collected at the following time points: day 0, day 1, day 3, day 5, and day 7. Samples from brain-dead organ donors were obtained on day 0, the day of the organ donation surgery. Urine samples were collected from recipients after transplantation through an externalized uretero-vesico-cutaneous stent and therefore exclusively reflected the αand π-GST content of the transplanted grafts.
Immunosuppression Events and Subgroups
All recipients received a triple immunosuppressant consisting of prednisolone, mycophenolate mofetil (MMF), and a calcineurin inhibitor. All deceased donor kidney recipients received tacrolimus, whereas living donor kidney recipients were treated with either tacrolimus or cyclosporine. Recipients were divided into subgroups according to the events in the first postoperative week: acute graft rejection (AGR, G1), calcineurin-induced nephrotoxicity (CNI, G2), both acute kidney rejection and calcineurin-induced nephrotoxicity (AGR + CNI, G3), delayed graft function (DGF, G4), and event-free (healthy, G5) subgroup (Figure 1 ). An acute graft rejection was confirmed by graft biopsy and classified according to the BANFF criteria. Calcineurin-induced nephrotoxicity was defined by serum levels of agents (tacrolimus >15 ng/mL, cyclosporin >250 ng/mL). It is worth noting that delayed graft function, characterized by the need for dialysis in the first week after transplantation, was not recorded in any of the living donor recipients. In case dialysis was required due to a known graft-damaging event such as AGR or CNI, those patients were enrolled in subgroups of primary cause and not defined as DGF. Recipients with no signs for any of the above events were considered healthy and were used as our control group.
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GST Analysis and Statistics
Urinary α-and π-GST values were measured using a commercially available ELISA test kit provided by Argutus Medical Ltd. (Dublin, Ireland). To consider the physiological differences in urine concentrations, α-and π-GST values were standardized to urine creatinine. The resulting unit for GST was ng/mg uCrea. Reference ranges of urinary α-and π-GST were determined as recommended from the measured GST values in the healthy population of this study group. For this purpose, the α-and π-GST values in the urine of healthy living donors were considered before donor nephrectomy. The reference interval for α-GST is 2.7-7.6 ng/mg uCrea and for π-GST 4.1-13 ng/mg uCrea in this study.
For statistical analysis, GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA) was used. Quantitative data are given as the mean and standard deviation. To compare normally distributed variables, t-tests such as Mann-Whitney and Wilcoxon were performed. For the comparison of multiple variables, we used two-way ANOVA; here we applied Tukey and Holm-Sidak tests for post hoc analysis of the subgroups. The area under the curve was calculated in ROC analysis and a log-rank (Mantel-Cox) test was performed in survival analysis. A p-value less than 0.05 was defined as significant.
Results
Demographic Data
There were no differences regarding gender and BMI between the patient groups. The mean eGFR before graft recovery or transplantation (d0) did not differ between the groups. Recipients of deceased donor kidneys were significantly older than those of living donors (58 ± 13 and 48 ± 15 respectively, p = 0.006), whereas the donor's age was not different. Cold as well as warm ischemic time were significantly higher in the deceased donor group (both p < 0.0001). The demographic data 
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α-and π-GST in Recipients
Neither α-nor π-GST correlated with age, BMI, and cold or warm ischemic time in any group. However, both GST isoenzymes correlated with renal function in living donors and in the healthy recipients subgroup. In deceased donor recipients and living donor recipients we observed acute rejection in four (13.4%) and eight patients (16%), calcineurin-induced nephrotoxicity in five (16.7%) and 12 (24%) patients, and both simultaneously in three (10%) and three (6%) patients, respectively. Delayed graft function occurred only with deceased donors (nine patients, 30%). Patients with an uneventful postoperative course in the deceased donor recipient group numbered nine (30%) and, in the living donor recipient group, 27 (54%). Both α-and π-GST were significantly elevated at 1st postoperative day (POD) in deceased donor recipients, with acute rejection when compared with the corresponding healthy subgroup (α-GST: Mean 473.5 ± 818 vs. 15.6 ± 21.2 ng/mg uCrea, p = 0.0094; π-GST: mean 477.8 ± 804 vs. 8 ± 6.4 ng/mg uCrea, p = 0.0023). In living donor recipients, only 
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Figure 5.
Correlation between urinary π-GST levels in recipients of brain-dead donors' grafts on POD 1, 3, and 7; and probability of graft survival without delayed graft function (DGF) during the first week after transplantation. 
α-and π-GST in Donors
α-and π-GST showed interesting results when measured in deceased donor urine before organ harvesting as they were elevated in those with poorer graft function after transplantation, and seemed to predict a foreseeable event such as acute rejection or delayed graft function, which was 3-to 8-fold more likely to occur than in those recipients with an uneventful course of treatment. α-GST stood out in the subgroup with both acute rejection and CNI toxicity (p = 0.02), while α-and π-GST were remarkably higher (but not significantly so) in the DGF subgroup compared to the control group ( Figure 6) . As for the predictive value of GST when measured in donor urine, α-GST stood out with significant results in the AGR subgroup when ROC curve analysis was performed, Figure 5 . Correlation between urinary π-GST levels in recipients of brain-dead donors' grafts on POD 1, 3, and 7; and probability of graft survival without delayed graft function (DGF) during the first week after transplantation.
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αand π-GST showed interesting results when measured in deceased donor urine before organ harvesting as they were elevated in those with poorer graft function after transplantation, and seemed to predict a foreseeable event such as acute rejection or delayed graft function, which was 3-to 8-fold more likely to occur than in those recipients with an uneventful course of treatment. α-GST stood out in the subgroup with both acute rejection and CNI toxicity (p = 0.02), while αand π-GST were remarkably higher (but not significantly so) in the DGF subgroup compared to the control group ( Figure 6) . As for the predictive value of GST when measured in donor urine, α-GST stood out with significant results in the AGR subgroup when ROC curve analysis was performed, and a cutoff value of >33.97 ng/mg uCrea was calculated (AUC, 0.86; sensitivity, 77.7%; specificity, 100%). Based on the donor's urinary α-GST alone, all four renal grafts from deceased donors that showed acute rejection in recipients were distinguished from those who had an AGR-free course in the survival curve analysis (p = 0.0109) (Figure 7) .
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Six-and 12-Months Graft Survival
We followed up recipients of the subgroups G1 (AGR) and G4 (DGF) at six and 12 months after transplantation, as correlations of α-and π-GST in those cohorts showed the most promising results. However, in subgroup G1 only one patient out of four lost the graft due to recruiting nephritis; in subgroup G4 all three grafts were lost due to death not associated with graft function (cancer or cardiac arrest).
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Six-and 12-Months Graft Survival
We followed up recipients of the subgroups G1 (AGR) and G4 (DGF) at six and 12 months after transplantation, as correlations of αand π-GST in those cohorts showed the most promising results. However, in subgroup G1 only one patient out of four lost the graft due to recruiting nephritis; in subgroup G4 all three grafts were lost due to death not associated with graft function (cancer or cardiac arrest).
Discussion
The results of our prospective study, evaluating urinary αand π-GST in deceased as well as living kidney donors and their corresponding recipients as biomarkers for graft quality and function, suggest the potential value of these enzymes. Previous studies showed the ability of urinary αand π-GST to predict acute renal damage in kidney graft recipients and demonstrated a release of these enzymes in malfunctioning grafts [10] [11] [12] [13] [14] [15] . However, none of these groups has compared the course of αand π-GST in donors as well as in corresponding recipients. In addition, we investigated the differences in the markers in two settings, brain-dead/deceased and living organ donation. Our analyses reveal that the determination of urinary π-GST concentration in deceased donor recipients, especially on the first day after graft transplantation, could be valuable and indicative of kidney allograft function and survival without AGR or DGF. Secondly, we found higher concentrations of αand π-GST in the urine of deceased kidney donors, whose grafts performed poorly in the corresponding recipients; α-GST was able to predict AGR before transplantation. A determination between the causes of impaired allograft function could not be reached by assessing urinary αand π-GST alone, though it is unlikely that in the complex setting of transplantation a single biomarker will reliably distinguish between the pathogenesis of multifactorial elements; therefore, the proposed markers should be seen as an useful tool in addition to established methods.
Research studies investigating αand π-GST in living donation are extremely limited: in our review of the literature we only found one publication on this issue, and this concerned liver rather than kidney transplantation [16] . Our findings showed lower concentrations of αand π-GST in the urine of living donor kidney recipients than in that of deceased donor kidney recipients. This was observed in almost all subgroups, and especially on POD 1. Except for a notable, yet insignificant, rise of π-GST in living donor recipients with AGR when compared to the control group, our results find no further significances of urinary αand π-GST in living donor recipients when harmful events occurred. Considering the superior organ quality and logistics in living donation transplantation, as demonstrated by over half of living donor grafts surviving the first week after transplantation event-free compared to 30% of deceased donor grafts, lower urinary concentrations of αnor π-GST in living donor transplantation are to be expected. Daemen et al. found a correlation between α-GST and warm ischemic time in grafts from donation after cardiac death [17] . In our study neither αnor π-GST had a proven correlation with ischemic time, although it should be noted that a different type of graft was investigated in the work mentioned.
The toxic effect of CNI agents on renal grafts and its association with the excretion of α-GST has been described in the past [10, 18] . Our results failed to indicate such a correlation in deceased or living donor recipients. This might be due to our definition of the toxic range of CNI serum levels. Therapeutic and toxic serum levels of several drugs and especially immunosuppressants have been known to be inconsistent and even overlapping [6, 19] . In the 1990s, serum levels of tacrolimus in the early period after transplantation were suggested to be below 20 ng/mL in order to avoid side effects, whereas later on levels above 15 ng/mg were proven to be associated with a higher risk of toxicity [20, 21] . On the other hand, the risk of acute rejection is significantly higher when there are low concentrations of the agent [22] . A helpful step would be to find the toxic serum level of immunosuppressants that is agreed upon by transplant communities; currently, despite all efforts, this varies significantly between transplant centers. Another concerning factor is the design of the study, which did not include daily and therefore more precise surveillance on that matter. In order to investigate the correlation between toxic exposure to immunosuppressants and the excretion of GST into the urine, a closer observation with more frequent sample collection is required.
DGF was observed only in deceased donor recipients in our study. It occurred with an incidence of 30%, which is similar to the findings of a recent work by Willicombe et al. [23] . Risk factors and characteristics of donors and recipients associated with DGF such as cold ischemic time and donor age have been established in previous publications [4, 5, 24] . However, taking these factors into consideration, it is to be expected that DGF is less common in living donation. It has been demonstrated that α-GST excretion would be increased in the case of DGF due to its location in the renal tubular system and the association between DGF and proximal tubular necrosis [8, 25] . On the other hand, π-GST has been shown to be of predictive value in terms of the need for dialysis in a publication by Seabra et al. including 245 patients with acute kidney injury [26] . Hall et al. investigated αand π-GST in a perfusate solution during machine perfusion of kidney allografts from deceased donors, and suggested an independent association between π-GST and DGF [27] . Our findings demonstrated the consistent significance of urinary π-GST in differentiating between DGF and normally functioning grafts when measured in deceased donor recipients. This was observed at several time points of the study and had a strong power of sensitivity and specificity. Little is known about the behavior of the proteins under dialysis, so it is unclear whether α-GST is more dialyzable than π-GST or the other way round. The sample collection from patients undergoing dialysis in our study did not occur with respect to dialysis time, which should be seen as another possible disturbance factor.
Further limitations of this study are the small number of patients in certain subgroups and the overall high standard deviations. We distinguished well between the causes of impaired graft function and took into consideration simultaneous events. The time frame of our observation was limited in that it focused only on the first week after transplantation. We believe that multiple serial samples and an extended study design would be beneficial in future projects.
Conclusions
In summary, the elevation of urinary π-GST in deceased donor kidney recipients at day 1 after kidney transplantation could be a helpful monitoring parameter, in addition to urinary output and serum creatinine, to determine graft function in recipients. It might be indicative of acute rejection or a need for dialysis. The measuring of urinary αand π-GST should also be considered in deceased donors as this seems to be of predictive value in terms of graft outcome and might help with assessing allograft quality. Our findings reveal an association between urinary α-GST in deceased donors and AGR in corresponding recipients. Thus, further investigation of αand π-GST in a larger population and daily sample collection should be considered. Although urinary αand π-GST in living kidney donation showed no relevant correlation with harmful events in our analyses, this is, to the best of our knowledge, the first study demonstrating differences in biomarkers between deceased and living kidney donation, so subsequent investigations will be needed in order to confirm or contradict our findings. 
